Slide 1: Immatics Corporate Presentation, March 2020
Immatics Corporate Presentation, March 2020 © 2020 Immatics. Not for further reproduction or distribution.
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation (“Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between ARYA Sciences Acquisition Corp. (“ARYA”) and ImmaticsBiot
Slide 3: Key Elements to Build a Global Leader in TCR-based Immunotherapies
Key Elements to Build a Global Leader in TCR-based Immunotherapies True Targets & Right TCRs Two technology platforms for the discovery of pHLA targets & T cell receptors Foundation to achieve the next advance in immunotherapy, particularly for solid tumors Proprietary Pipeline of Two Distinct Produ
Slide 4: Making a Difference – Delivering the Power of T cells to Cancer Patients
Making a Difference – Delivering the Power of T cells to Cancer Patients Discovering Targets beyond the Cancer Cell Surface to Unlock Immunotherapies for Solid Cancers CAR-T and Antibody-based TCR-based Approaches Approaches CAR- T cell receptors (TCRs) access T successful in hematological indicatio
Slide 5: Proprietary Pipeline of Adoptive Cell Therapy (ACT) & TCR Bispecifics
Proprietary Pipeline of Adoptive Cell Therapy (ACT) & TCR Bispecifics Developing Novel Treatments Across Two Distinct Product Classes 5
Slide 6: Recent Major Strategic Partnerships with World-leading Industry Partners
Recent Major Strategic Partnerships with World-leading Industry Partners Validation of Immatics’ Unique Technologies and Expertise 2017 2018 2019 “Developing Novel Bispecific 2020 Cancer Immunotherapies” “Next Generation Bispecific 2 Immatics targets Cancer Immunotherapies” Immatics XPRESIDENT®, “St
Slide 7: Immatics – Delivering the Power of T cells to Cancer Patients
Immatics – Delivering the Power of T cells to Cancer Patients IDENTIFY DELIVER PIONEER True Targets Therapeutic Pipelines Multi-Target Personalized and Right TCRs of ACT and TCR Bispecifics Precision Immunotherapy Two Proprietary Technology Platforms Two Distinct Product Classes Personalized & Preci
Slide 8: Discovery of True Cancer Targets – XPRESIDENT Technology Platform
Discovery of True Cancer Targets – XPRESIDENT® Technology Platform Prioritization of >200 pHLA Targets Covering All Target Classes TARGET CLASSES 1. Well known and characterized parent pHLA DATABASE protein e.g. MAGE family cancer testis based on primary tissues antigens Cancer tissues 2. Unknown or
Slide 9: Development of the Right TCR – XCEPTOR Technology Platform
Development of the Right TCR – XCEPTOR™ Technology Platform Pioneering Novel Therapeutic Modalities: T cell Receptors (TCRs) for ACT and Bispecifics Adoptive Cell Therapy TCR Bispecifics ACTengine® T cell engaging ACTallo® receptor (TCER™) Affinity-maturated natural Proprietary XCEPTOR™ Platform TCR
Slide 10: Immatics – Delivering the Power of T cells to Cancer Patients
Immatics – Delivering the Power of T cells to Cancer Patients IDENTIFY DELIVER PIONEER True Targets Therapeutic Pipelines Multi-Target Personalized and Right TCRs of ACT and TCR Bispecifics Precision Immunotherapy Two Proprietary Technology Platforms Two Distinct Product Classes Personalized & Preci
Slide 11: ACTengine – Engineered TCR-T Therapy
ACTengine® – Engineered TCR-T Therapy Autologous, Genetically Modified T cells Expressing a Novel TCR HLA-A*02 positive Cancer Lymphodepletion (Flu/ Cy) patient Biopsy: Biomarker profiling ACTengine® IMA200 Series T cell infusion Low dose IL-2 Proprietary TCR Approach One target/TCR per trial Target
Slide 12: pHLA Target Characteristics of Immatics' ACT Lead Programs
pHLA Target Characteristics of Immatics’ ACT Lead Programs Comparison of our Frontrunner Targets to Clinically Validated NY-ESO-1 Ongoing clinical ACTengine® trials NY-ESO-15 COL6A3 exon 6 IMA204 Naturally presented Yes1 Yes2 Specificity class3 1 2 Copy number 10-504 100-7002 Tumor types with Synovi
Slide 13: ACTengine – Optimized Manufacturing
ACTengine® – Optimized Manufacturing Established cGMP Capacities to Advance Next-Generation Cell Manufacturing Developments Leukapheresis Infusion-Ready Manufacturing for ongoing ACT programs ✓ Proprietary short manufacturing process designed to produce phenotypically younger, better persisting T ce
Slide 14: ACTengine – Encouraging First Patient Responses
ACTengine® – Encouraging First Patient Responses Enrollment Status and Exemplary Preliminary Biological Data on First Patients Treated ACTengine® Studies Enrollment Status 22 HLA-A*02:01-positive pts with target-positive biopsy Products successfully manufactured for 10/10 patients & first 4 patients
Slide 15: ACTallo – Next Generation Off-the-shelf TCR-T Therapy
ACTallo® – Next Generation Off-the-shelf TCR-T Therapy Allogenic, Genetically Modified ãäT cells Expressing a Novel TCR ACTallo® T cells effectively kill tumor cells in vitro IMA301 target-positive tumor cells: U20S (~250 target copies/ cell) HLA-A*02 positive tumor cells only áâT cells (control) +
Slide 16: TCER – Immatics' TCR Bispecifics Mode of Action
TCER™ – Immatics’ TCR Bispecifics Mode of Action 16
Slide 17: TCER – Engineering an off-the-shelf Biologic
TCER™ – Engineering an off-the-shelf Biologic Adoptive Cell Therapy TCR Bispecifics ACTengine® T cell engaging ACTallo® receptor (TCER™) Affinity-maturated natural Proprietary XCEPTOR™ Platform TCR variable domains with nanomolar Natural or optimized natural TCR TCR Discovery, affinity and favorable
Slide 18: TCER – Summary IMA401 Lead Candidate
TCER™ – Summary IMA401 Lead Candidate Proprietary TCR Bispecifics Format TCER™ design confers superior potency and stability compared to multiple Tumor Xenograft Mouse Model alternative bispecific formats Significantly extended half life as compared to competitor molecules Very High Potency Very low
Slide 19: Immatics – Delivering the Power of T cells to Cancer Patients
Immatics – Delivering the Power of T cells to Cancer Patients IDENTIFY DELIVER PIONEER True Targets Therapeutic Pipelines Multi-Target Personalized and Right TCRs of ACT and TCR Bispecifics Precision Immunotherapy Two Proprietary Technology Platforms Two Distinct Product Classes Personalized & Preci
Slide 20: ACTolog – Pioneering Personalized Multi-target T cell Therapy
ACTolog® – Pinoneering Personalized Multi-target T cell Therapy Pilot Trial Using Autologous T cells Expressing Endogenous TCRs HLA-A*02 positive ACTolog® IMA101 Cancer Personalized multi-target T cell therapy Lymphodepletion (Flu/ Cy) Biopsy: Biomarker profiling Approach patient T cell infusion usi
Slide 21: ACTolog – Preliminary Clinical Data as of January 2020
ACTolog® – Pioneering Personalized Multi-target T cell Therapy Preliminary Clinical Data as of January 2020 T cell Persistence in Blood 12 patients treated (various solid tumor indications). Patients Median duration of disease of the patients was 4 years (range 2-18 years) with a median of 6 previou
Slide 22: Immatics' Multi-target TCR-T Strategy and Vision
Immatics’ Multi-target TCR-T Strategy and Vision Addressing Major Challenges in Immuno-oncology to Make a Therapeutic Difference ACTolog® ACTolog® = Multi-target Cell Therapy PILOT study 1 7 Immatics’ targets Delivered initial clinical data 2019 Screening completed ACTengine® ACTengine® BLA filing(s
Slide 23: The Leadership Team
The Leadership Team Experienced Global Leadership Team Across Europe and the US Harpreet Singh Rainer Kramer Chief Executive Officer Chief Business Officer Thomas Ulmer Steffen Walter Chief Financial Officer Chief Scientific Officer US Carsten Reinhardt Stephen Eck Chief Medical Officer Chief Medica
Slide 24: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans-Atlantic Organization United to Build a Global Leader in T cell Receptor-based Immunotherapies Tübingen, Germany, 120 FTEs Senior Leadership, Research and Development (XPRESIDENT®, XCEPTOR™, TCER™), Translational Development, Clinical Operations, Finance,
Slide 25: Continuously Growing IP Portfolio Protecting Proprietary Know-How
Continuously Growing IP Portfolio Protecting Proprietary Know-How Immatics’ Patent Estate – Territorial Coverage ~ 5000 applications and patents >100 patent families IP protection on >8000 cancer targets, TCRs and technology Immatics files patent applications in all major countries and regions >220
Slide 26: Immatics and ARYA to Merge – Transaction Summary
Immatics and ARYA to Merge Transaction Summary Immatics GmbH (“Immatics”) and ARYA Sciences Acquisition Corp (“ARYA”, Nasdaq: ARYA) to merge pursuant to a business combination agreement to be entered into among Immatics and a newly formed entity formed for the purpose of consummating the transaction
Slide 27: Terms of Transaction
Terms of Transaction Pro Forma Valuation and Ownership Pro Forma Valuation Sources of Funds (1,3) Uses of Funds (1) Pro Forma Shares Outstanding 63,383,750 Share Price (illustrative) $ 10.00 Cash Held in Trust $ 147,842,000 PF Equity Value $ 633,837,500 Issuance of Shares $ 350,000,000 Stock Conside
Slide 28: Use of Proceeds
Use of Proceeds After Deal Closure the Combined Company is Expected to be well Capitalized Approximately $319 million(1) of post-transaction cash on the combined company balance sheet to pursue clinical development and platform enhancements Cash runway envisaged for 3+ years Projected proceeds will
Slide 29: Milestones to Achieve the Next Advance in Immunotherapy
Milestones to Achieve the Next Advance in Immunotherapy Immatics‘ Achievements to Date Near-Term Value Inflection Points >200 prioritized targets Projected major value inflections 2020-2021 are expected to lead to a significant valuation step up Eight proprietary pipeline programs, four of them in c
Slide 30: Thank you
Thank you www.immatics.com Please contact us via partnering@immatics.com to learn more about partnering and licensing opportunities utilizing our platform technologies XPRESIDENT®, XCEPTOR™, IMADetect™ and AbsQuant™. 30